期刊文献+

2型糖尿病伴脂肪肝与瘦素及血脂代谢的相关分析 被引量:1

Leptin and lipid metabolism in type 2 diabetic patients with fatty liver disease
下载PDF
导出
摘要 目的探讨2型糖尿病(DM)伴脂肪肝与瘦素及脂代谢紊乱的相关性。方法随机选择我院内分泌科200例2型糖尿病患者,其中合并脂肪肝组89例,非脂肪肝组111例,对其进行有关临床、病史、生化指标、瘦素、C肽与肝脏B超检查。结果2型糖尿病伴脂肪肝组与不伴脂肪肝组比较体质量指数(BMI)(27.68±4.00)vs(24.72±3.07)kg/m2、甘油三酯(TG)(2.88±3.19)mmol/Lvs(1.74±1.18)mmol/L、1小时C肽(4.23±2.87)μg/Lvs(2.32±1.97)μg/L、2小时C肽(4.43±2.93)μg/Lvs(2.71±1.54)μg/L、瘦素(13.08±8.88)μg/Lvs(8.63±5.45)μg/L,水平明显增高。Logistic逐步回归分析显示1小时C肽、瘦素、甘油三酯水平与脂肪肝的发生呈正相关(r=0.005、0.002、0.040)。结论TG、1小时C肽、瘦素是影响2型糖尿病脂肪肝发生的主要影响因素。 Objevtive To study leptin and lipid metabolism in type 2 diabetic patients with fatty liver. Methods Selected 200 inpatients and outpatients in endocrinology department of Yuhuangding Hospital randomly of which 89 patients were with fatty liver, 111 patients without fatty liver, a set of examinations including clinic history, biochemical test, leptin, C-peptide and liver ultrasound were carried out. Results Body mass index(BMI) (27.68± 4.00) kg/m±vs (24.72 ± 3.07) kg/m^2 , triglyceride (TG) (2.88 ± 3.19) mmol/L vs (1.74 ± 1.18) mmol/L, 1 h C- peptide (4.23± 2.87) μg/L vs (2.32 ± 1.97) μg/L, 2 h C-peptide (4.43 ± 2.93) μg/L vs (2.71 ± 1.54) μg/L and leptin (13.08±8.88) μg/L vs (8.63±5.45) μg/L in type 2 diabetes with fatty liver group were higher than in type 2 diabetes without fatty liver group. The result of logistic regression indicates that 1 h C-peptide, leptin, and TG are associative with fatty liver ( r = 0. 005,0. 002, 0. 040). Conclusion TG, 1 h C-peptide and leptin are important associative factors in the patients of type 2 diabetes with fatty liver disease.
出处 《临床荟萃》 CAS 北大核心 2005年第21期1204-1206,共3页 Clinical Focus
关键词 糖尿病 非胰岛素依赖型 脂肪肝 脂代谢 瘦素 diabetes, mellitus, non-insulin-dependent fatty liver disease lipide metabolism leptin
  • 相关文献

参考文献4

共引文献1375

同被引文献24

  • 1范耀东,刘玉洁.2型糖尿病患者脂蛋白(a)水平与冠状动脉病变的关系[J].天津医药,2004,32(8):471-473. 被引量:4
  • 2陈小雨,廖珊.脂质代谢与2型糖尿病合并胆囊结石的关系探讨[J].现代中西医结合杂志,2005,14(21):2805-2806. 被引量:1
  • 3魏广玉.空腹血脂正常的2型糖尿病糖餐后血脂、血糖的相关关系[J].实用糖尿病杂志,2006,2(4):22-23. 被引量:5
  • 4Taskinen MR. Diabetic dyslipidaemia :from basic research to clinical practice [ J ]. Diabetologia,2003,46:734 - 8.
  • 5Witold PP, Katarzyna W,Tomasz P. Treatment of dyslipidemia in patients with diabetes mellitus [ J ]. Pharmacological Reports, 2005, 57:11.
  • 6Bloomgarden ZT. Perspectives on the news. Approaches to cardiovascular disease and its treatment[ J]. Diabetes Care ,2003,26:3342 -8.
  • 7Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance on type 2 diabetes [ J ]. Endocr Rev,2002,23:201 - 29.
  • 8Chirieac DV,Chirieac LR, Corseni JP, et al. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production [ J ]. Am J Physiol Endocrinol Metab, 2000,279 : E1003 - 11.
  • 9Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes [ J]. Diabetes Metab Res Rev,2002,18:484 - 90.
  • 10Rafael C, Beneridge DJ, Statins D. Statins and diabets[ J]. Seminars in Vascular Medicine,2004,4:322.

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部